Home › Funds › PSP Research LLC › TGTX
PSP Research LLC position in TGTX
TG THERAPEUTICS · Health Care
PSP Research LLC reported holding 5,000 shares of TGTX (TG THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$279K, representing 0.19% of its reported portfolio and ranking #10 among its reported holdings. PSP Research LLC has disclosed TGTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR
How PSP Research LLC's TGTX position evolved
PSP Research LLC first disclosed a stake in TGTX in Q4 2025 at 17,807 shares (US$531K). The position peaked in Q2 2026 at 10,000 shares, worth US$549K. Across 4 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 5,000 shares valued at US$279K — a reduction of -5,000 shares quarter over quarter.. Notable position changes include a 27% trim in Q1 2026 (shares rose 65% over the following quarter), a 50% trim in Q3 2026 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 17.81K | $530.83K | New |
| Q1 2026 | 13.00K | $431.86K | Reduce |
| Q2 2026 | 10.00K | $549.40K | Reduce |
| Q3 2026 | 5.00K | $278.90K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TGTX and 13F data
TGTX (TG THERAPEUTICS) is a Health Care company. 53 other funds we track also report a position in TGTX — the largest reported positions include Soleus Capital Management, L.P. (US$160.9M), CONGRESS ASSET MANAGEMENT CO (US$145.4M), Penn Capital Management Company, LLC (US$29.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TGTX
- Soleus Capital Management, L.P. 2.93M sh · $160.86M · Q2 2026
- CONGRESS ASSET MANAGEMENT CO 2.61M sh · $145.39M · Q3 2026
- Penn Capital Management Company, LLC 536.07K sh · $29.51M · Q2 2026
- Opaleye Management Inc. 535.00K sh · $29.39M · Q2 2026
- Occam Crest Management LP 425.00K sh · $22.73M · Q2 2026
- 683 Capital Management, LLC 389.08K sh · $21.38M · Q2 2026
More on PSP Research LLC
FAQ
How long has PSP Research LLC held TGTX?
PSP Research LLC has disclosed TGTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is PSP Research LLC's current position in TGTX?
As of Q3 2026, PSP Research LLC holds 5.00K shares of TGTX (TG THERAPEUTICS), valued at $278.90K, representing 0.19% of its reported portfolio and ranking #10.
Has PSP Research LLC been buying or selling TGTX?
In the latest 13F filing (Q3 2026), PSP Research LLC reduced its position in TGTX. The position peaked in Q2 2026 at 10.00K shares.
Which other funds hold TGTX?
Other major institutional holders of TGTX include Soleus Capital Management, L.P., CONGRESS ASSET MANAGEMENT CO, Penn Capital Management Company, LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.